These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 31706158)
21. A critical appraisal of the selegiline transdermal system for major depressive disorder. Bied AM; Kim J; Schwartz TL Expert Rev Clin Pharmacol; 2015; 8(6):673-81. PubMed ID: 26427518 [TBL] [Abstract][Full Text] [Related]
22. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. Shiroma PR; Johns B; Kuskowski M; Wels J; Thuras P; Albott CS; Lim KO J Affect Disord; 2014 Feb; 155():123-9. PubMed ID: 24268616 [TBL] [Abstract][Full Text] [Related]
23. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT. Allen AP; Naughton M; Dowling J; Walsh A; Ismail F; Shorten G; Scott L; McLoughlin DM; Cryan JF; Dinan TG; Clarke G J Affect Disord; 2015 Nov; 186():306-11. PubMed ID: 26275358 [TBL] [Abstract][Full Text] [Related]
31. Ineffectiveness of Repeated Intravenous Ketamine Infusions in Treatment-Resistant Depression After a Post-Ketamine Relapse: Time for a Rethink? López-Díaz Á; Fernández-González JL J Clin Psychopharmacol; 2018 Oct; 38(5):534-536. PubMed ID: 30106877 [No Abstract] [Full Text] [Related]
32. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study. Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333 [TBL] [Abstract][Full Text] [Related]
33. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436 [TBL] [Abstract][Full Text] [Related]
34. Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial. Gálvez V; Li A; Huggins C; Glue P; Martin D; Somogyi AA; Alonzo A; Rodgers A; Mitchell PB; Loo CK J Psychopharmacol; 2018 Apr; 32(4):397-407. PubMed ID: 29542371 [TBL] [Abstract][Full Text] [Related]
39. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273 [TBL] [Abstract][Full Text] [Related]
40. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. Amsterdam JD; Bodkin JA J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]